However, given this emerging body of work, a detailed assessment of PAK1 copy number alteration and validation experiments using small molecule inhibitors to evaluate PAK1 catalytic inhibition in breast cancer are still lacking. This evidence concerns the gene PAK1 and breast carcinoma.